Recently, In analysts report revealed to investors on 6 December, Madrigal Pharmaceuticals (mdgl) shares have had their "Buy" Rating reconfirmed by investment analysts at H.C. Wainwright, who now has a $105 price target on company. Of those analysts, 4 rate stock as a Strong Buy, 0 rate it as Hold, and just no analyst rates it as a Moderate Sell. HC Wainwright's target price would suggest a potential upside of 126.78% from the company's previous close.
MDGL has been the subject of several other research reports. Roth Capital started coverage on shares of Madrigal Pharmaceuticals in a research note on Thursday, October 19th. They set a buy rating and a $62.00 price target for the company. HC Wainwright assumed coverage on Madrigal Pharmaceuticals in a research report on Wednesday, November 29th. They issued a "buy" rating and a $54.00 price target for the company. JMP Securities lifted their price target on shares of Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the company an outperform rating in a research report on Friday, October 13th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Madrigal Pharmaceuticals now has an average rating of "Buy" and a consensus target price of $78.75. 86,700 shares of the company's stock traded hands, compared to its average volume of 44,074. Madrigal Pharmaceuticals has a fifty-two week low of $13.09 and a fifty-two week high of $53.00.
Gunmen Kidnap Former Nigerian Sports Minister Sango Damishi And Son
He said, "The kidnappers are demanding N100m". "The family spoke with him and he assured them that he is safe". Mapis, however, said that no one had contacted the family so far. "I am on my way to Abuja".
Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.79) by $0.11. analysts expect that Madrigal Pharmaceuticals will post -2.57 EPS for the current year.
Institutional investors now hold around $124 million or 66.7% in MDGL stock. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Madrigal Pharmaceuticals during the 1st quarter worth approximately $321,000. Northern Trust Corp increased its stake in shares of Madrigal Pharmaceuticals by 151.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 12,945 shares of the biopharmaceutical company's stock worth $582,000 after buying an additional 1,963 shares in the last quarter. Fmr Llc owns $25.63 million in Madrigal Pharmaceuticals, Inc., which represents roughly 2.62% of the company's market cap and approximately 20.67% of the institutional ownership. State Street Corp bought a new stake in Madrigal Pharmaceuticals during the 2nd quarter valued at approximately $539,000. Finally, VHCP Management II LLC acquired a new position in shares of Madrigal Pharmaceuticals in the 3rd quarter valued at $1,349,000.
DISH Network Corp (DISH) Holdings Boosted by Brown Advisory Inc
After $0.57 actual EPS reported by DISH Network Corporation for the previous quarter, Wall Street now forecasts 7.02 % EPS growth. The stock of Marvell Technology Group Ltd. (NASDAQ:MRVL) earned "Neutral" rating by Susquehanna on Tuesday, September 20.
TRADEMARK VIOLATION WARNING: This report was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another site, it was copied illegally and republished in violation of United States and global trademark & copyright law.
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH).
Share Rating Recap: Helios and Matsn Ana (HMNY)
In Play Stocks are volatile enough to produce good risk and reward trading opportunities for both bull and bear traders intraday. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues.